SMIM22基因在前列腺癌组织中的表达及与其临床预后的关系  

Expression and predictive effect of SMIM22 in prostate cancer tissue

作　　者：石露[1] 朱瑞霞[2] 李飞[3] Shi Lu;Zhu Ruixia;Li Fei(Department of Operating Room,the People's Hospital of Rugao Ciry,Rugao 226500,China;Department of Central Laboralory,Changhou No.2 Hospial Afilialed 10 Nanjing Medical Univer-sity,Changzhou 213000,China;Depurtment of Urology,the Peoples Hospial of Rugoo City,Rugao 226500,China.)

机构地区：[1]江苏省如皋市人民医院手术室,如皋226500 [2]南京医科大学附属常州第二医院中心实验室,常州213000 [3]江苏省如皋市人民医院泌尿外科,如皋226500

出　　处：《国际泌尿系统杂志》2021年第2期249-253,共5页International Journal of Urology and Nephrology

基　　金：南通市市级科技计划指导性项目(MSZ18042)。

摘　　要：目的探讨小整合膜蛋白22(SMIM22)基因在前列腺癌(PCa)组织中的表达以及与其临床预后的关系。方法收集2018年至2019年南京医科大学附属常州二院的20例前列腺组织样本,其中PCa 10例,正常前列腺组织10例。采用t检验分析癌基因组图谱(TCGA)数据库和GE0PCa基因表达谱芯片数据中PCa组织样本和正常前列腺组织样本SMIM22miRNA表达水平的差异。利用实时荧光定量PCR技术分析SMIM22表达水平与临床病理指标之间的相关性。使用Kaplan-Meier法和Cox比例风险回归模型进行SMIM22表达水平与根治性切除术后生化复发的关系研究。结果在TCGA数据库中PCa组织和正常前列腺组织中SMIM22表达水平分别为(75.5+3.7)和(28.7士3.3),差异有统计学意义(P<0.05);其中在GSE35988数据集中PCa组织和正常前列腺组织SMIM22表达水平分别为(1.17+0.28)和(-0.06+0.16),差异有统计学意义(P<0.05)。临床标本经RT-qPCR检测发现PCa组织中SMIM22 miRNA水平高于正常前列腺组织,差异有统计学意义(P<0.05)。单因素生存分析结果显示SMIM22是术后生化复发的影响因素(HR=0.502,95%CI;0.297~0.848,P=0.010)。多因素生存分析结果显示SMIM22是术后生化复发的独立影响因素(HR=0.573,95%CI:0.338~0.970,P=0.038),而且其预测作用独立于Gleason评分和病理T分期。结论SMIM22在PCa组织中高表达,根治性切除术后患者PCa组织中SMIM22表达水平可作为术后生化复发的辅助指标。Objective To investigate the expression profile of SMIM22 in prostate tissue and the association of its expression level with post-operative biochemical relapse.Methods From 2018 to 2019,twenty prostate tissue samples were taken in Changzhou second affiliated hospital of Nanjing medical university.The differential expression of SMIM22 miRNA between prostate cancer and normal prostate tissue was conducted via Students t test using data deprived from TCGA and GSE35988.The relative expression level of SMIM22 miRNA in 10 prostate cancer tissues and 10 normal prostate tissues was detected via quantitative real-time PCR.The relationship between SMIM22 expression levels and the clinic pathological parameters was investigated via Chi-square test.Finally,the Kaplan-Meier plot and Cox proportional hazard regression model was used to assess the predictive ability of SMIM22 expression level on biochemical recurrence after radical prostatectomy.Results In TCGA dataset,the expression level of SMIM22 miRNA in prostate cancer and normal prostate tissue were(75.5±3.7)and(28.7±3.3),respectively,while in GSE35988 the expression levels were(1.17±0.28)and(-0.06±0.16),respectively.The differences lietween two groups in both datasets were statistically significant.The RT-qPCR results showed that the relative expression level of SMIM22 miRNA in prostate cancer tissue was higher than that of normal prostate tissue.Survival analysis showed that lower SMIM22 expression level was a risk factor for post-operative biochemical relapse(H R=0.573,95%C l:0.338-0.970,P=0.038),independent of Gleason score and pathological T slage.Conclusions SMIM22 miRNA is overexpressed in prostate cancer.Its expression level can predict biochemical relapse after radical prostatectomy.

关 键 词：前列腺肿瘤 小整合膜蛋白22 前列腺切除术 

分 类 号：R737.25[医药卫生—肿瘤]